Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.
Latest from Jessica Merrill
CEO Rob Davis said the company is still interested in completing more deals after announcing the $5.7bn acquisition of Terns net of cash and mentioned immunology as an area of interest.
As a pioneer in antibody-drug conjugates, Daiichi Sankyo has seen both breakthroughs and setbacks in advancing the modality. CEO Ken Keller told In Vivo the company had turned to next generation biomarker technologies to navigate these challenges and sharpen its R&D strategy.
CEO Matt Gline talked to Scrip about preparing for the launch of brepocitinib in dermatomyositis, lessons learned from Vtama, and how smaller biopharmas are delivering launch successes.
The company announced positive Phase III data and plans to file an sNDA for Arikayce in newly diagnosed patients with MAC lung disease, a potential blockbuster indication.
The company announced the first Phase III data testing the GIP/GLP-1/glucagon agonist in diabetic patients, showing reductions in blood sugar and superior weight loss to Mounjaro.
The company licensed worldwide rights to the IBAT inhibitor from GSK just days ahead of the drug’s US FDA approval for cholestatic pruritus associated with primary biliary cholangitis.